Insulet (NASDAQ:PODD) Now Covered by Stifel Nicolaus

Key Points

• Research firm Stifel Nicolaus has initiated coverage on Insulet (NASDAQ:PODD), assigning a "buy" rating with a price target of $370.00, indicating a potential upside of 13.20% from the current stock price.
• Insulet recently reported earnings that beat expectations, with a quarterly EPS of $1.17 against a consensus estimate of $0.92, reflecting a 32.9% year-over-year revenue growth.
• Analysts' consensus rating for Insulet is "Moderate Buy," with 19 out of 22 analysts issuing a "buy" rating, and the average price target set at $352.11.

Research analysts at Stifel Nicolaus initiated coverage on shares of Insulet (NASDAQ:PODD - Get Free Report) in a report released on Tuesday. The firm set a "buy" rating and a $370.00 price target on the medical instruments supplier's stock. Stifel Nicolaus' price target points to a potential upside of 13.20% from the stock's current price.

Several other analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada lifted their price objective on shares of Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a research report on Friday, October 10th. Rothschild & Co Redburn lifted their price objective on shares of Insulet from $350.00 to $370.00 and gave the company a "buy" rating in a research report on Friday, October 3rd. Oppenheimer lifted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Finally, The Goldman Sachs Group lowered their target price on shares of Insulet from $399.00 to $375.00 and set a "buy" rating on the stock in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $352.11.

Insulet Trading Up 2.6%

Insulet stock opened at $326.85 on Tuesday. The company has a market cap of $23.01 billion, a P/E ratio of 99.35, a PEG ratio of 2.66 and a beta of 1.40. The firm's 50-day moving average is $326.66 and its 200-day moving average is $303.10. Insulet has a 1 year low of $226.50 and a 1 year high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Hedge Funds Weigh In On Insulet

Hedge funds have recently made changes to their positions in the business. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the 1st quarter worth approximately $26,000. Larson Financial Group LLC boosted its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares during the period. Golden State Wealth Management LLC increased its position in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 69 shares in the last quarter. SouthState Corp increased its position in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Finally, Kozak & Associates Inc. purchased a new position in shares of Insulet in the second quarter worth approximately $32,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.